Sort   by:  
 Page size 
ProteomicsNon-canonical EphA2 signaling is a driver of tumor-endothelial cell interactions and metastatic dissemination in BRAF inhibitor resistant melanoma: Phosphoproteomics
Acquired BRAF/MEK inhibitor resistance in melanoma results in a new transcriptional state associated with increased risk of metastasis. Here, we identified non-canonical EphA2 signaling as a driver of the resistance-associated metastatic state. We used mass spectrometry-based proteomic and phenotypi...
ORGANISM(S): Homo sapiens (Human) 
2020-11-18 | PXD020241 | Pride
Melanoma Phosphoproteomics. ephrin a2 Braf inhibitor Drug resistance 
ProteomicsNon-canonical EphA2 signaling is a driver of tumor-endothelial cell interactions and metastatic dissemination in BRAF inhibitor resistant melanoma
Acquired BRAF/MEK inhibitor resistance in melanoma results in a new transcriptional state associated with increased risk of metastasis. Here, we identified non-canonical EphA2 signaling as a driver of the resistance-associated metastatic state. We used mass spectrometry-based proteomic and phenotypi...
ORGANISM(S): Homo sapiens (Human) 
2020-11-18 | PXD020250 | Pride
Phosphotyrosine. ephrin a2 Melanoma Braf inhibitor Drug resistance 
ProteomicsNon-canonical EphA2 signaling is a driver of tumor-endothelial cell interactions and metastatic dissemination in BRAF inhibitor resistant melanoma: Expression Proteomics
Acquired BRAF/MEK inhibitor resistance in melanoma results in a new transcriptional state associated with increased risk of metastasis. Here, we identified non-canonical EphA2 signaling as a driver of the resistance-associated metastatic state. We used mass spectrometry-based proteomic and phenotypi...
ORGANISM(S): Homo sapiens (Human) 
2020-11-18 | PXD020242 | Pride
Melanoma Braf inhibitor Expression proteomics. ephrin a2 Drug resistance 
Sort   by:  
 Page size